Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children
Tài liệu tham khảo
Adam de Beaumais, 2012, Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia, Eur. J. Clin. Pharmacol., 68, 1233, 10.1007/s00228-012-1251-4
Angelilli, 2000, Palatability of oral antibiotics among children in an urban primary care center, Arch. Pediatr. Adolesc. Med., 154, 267, 10.1001/archpedi.154.3.267
Anon, na-a, EMA. EMA/CHMP/PEG/194810/2005.
Anon, na-b, EMA/CHMP/QWP/180157/2011.
Anon, na-c, EMA Guideline on non-clinical local tolerance testing of medicinal products.
Anon, na-d EMA. EMA/CPMP/ICH E11.
Balis, 1998, Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study, Blood, 92, 3569, 10.1182/blood.V92.10.3569
Blumer, 1999, Off-label uses of drugs in children, Pediatrics, 104, 598, 10.1542/peds.104.S3.598
Breitkreutz, 2007, Paediatric and geriatric drug delivery, Expert Opin. Drug Deliv., 4, 37, 10.1517/17425247.4.1.37
Breitkreutz, 2007, Comparative in vitro studies on different 6-mercaptopurine formulations for use in children, Paediatr. Perinat. Drug Ther., 8, 31, 10.1185/146300907X167817
Clemmensen, 2014, The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol, Pediatr. Blood Cancer, 61, 653, 10.1002/pbc.24867
Conroy, 2003, Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO, 14, 42, 10.1093/annonc/mdg031
Darbre, 2008, Paraben esters: review of recent studies of endocrine toxicity, absorption, esterase and human exposure, and discussion of potential human health risks, J. Appl. Toxicol. JAT, 28, 561, 10.1002/jat.1358
De Lemos, 2007, Interaction between mercaptopurine and milk, J. Oncol. Pharm. Pract. Off. Publ. Int. Soc. Oncol. Pharm. Pract., 13, 237, 10.1177/1078155207080802
Dervieux, 1998, Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC, Clin. Chem., 44, 551, 10.1093/clinchem/44.3.551
Hanff, 2014, A novel 6-mercaptopurine oral liquid formulation for pediatric acute lymphoblastic leukemia patients — results of a randomized clinical trial, Int. J. Clin. Pharmacol. Ther., 52, 653, 10.5414/CP202054
Légifrance, 1992
Lilleyman, 1996, Non-compliance with oral chemotherapy in childhood leukaemia, BMJ, 313, 1219, 10.1136/bmj.313.7067.1219
Matsui, 2007, Current issues in pediatric medication adherence, Paediatr. Drugs, 9, 283, 10.2165/00148581-200709050-00001
Mulla, 2012, A step toward more accurate dosing for mercaptopurine in childhood acute lymphoblastic leukemia, J. Clin. Pharmacol., 52, 1610, 10.1177/0091270011423663
Nahata, 1999, Inadequate pharmacotherapeutic data for drugs used in children: what can be done?, Paediatr. Drugs, 1, 245, 10.2165/00128072-199901040-00001
Relling, 2013, Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update, Clin. Pharmacol. Ther., 93, 324, 10.1038/clpt.2013.4
Schirm E, Tobi H, de Vries TW et al. Lack of appropriate formulations of medicines for children in the community. Acta Paediatr. 1992. 2003;92(12):1486–9 (Oslo Nor).
Schmiegelow, 2014, Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction, J. Pediatr. Hematol. Oncol., 36, 503, 10.1097/MPH.0000000000000206